Description
Technical Specifications
-
Synonyms: Mod GRF 1-29, Tetrasubstituted GRF 1-29
-
Sequence Length: 29 Amino Acids (Modified)
-
Purity: ≥99% (HPLC Verified)
-
Form: Lyophilized White Powder
-
Molar Mass: ~3367.9 g/mol
-
PubChem CID: 9924584
Mechanism: Natural Pulsatile Emulation
The primary research utility of CJC-1295 No DAC lies in its pharmacokinetic profile. Unlike the “DAC” (Drug Affinity Complex) variant, which binds to albumin for days creating a continuous “bleed” of growth hormone, Mod GRF 1-29 mimics the organism’s natural circadian rhythm.
-
Pulsatile Release: The approximate 30-minute half-life allows for distinct, high-amplitude spikes in Growth Hormone (GH) secretion followed by a return to baseline.
-
Pituitary Sensitivity: By avoiding the “GH bleed” associated with long-acting GHRH analogs, Mod GRF 1-29 minimizes the risk of downregulating GHRH receptors on the anterior pituitary. This makes it the preferred compound for studies attempting to emulate natural physiological signaling.
Research Synergy: The “GHRH + GHRP” Protocol
CJC-1295 No DAC is frequently utilized in conjunction with Ipamorelin or GHRP-6 to investigate neuroendocrine amplification. This pairing addresses the two rate-limiting factors of the somatotropic axis:
-
The Accelerator (CJC-1295 No DAC): Acts as a Growth Hormone Releasing Hormone (GHRH) agonist, binding to pituitary receptors to stimulate GH production.
-
The Brake Release (Ipamorelin): Acts as a Growth Hormone Releasing Peptide (GHRP), which mitigates the inhibitory effect of Somatostatin.
-
The Outcome: Research suggests that co-administration creates a synergistic effect where the total GH release is significantly greater than the sum of the two peptides administered individually.
This research peptide undergoes rigorous quality control and stability testing to ensure maximum integrity for scientific applications. Each batch is manufactured under strict laboratory conditions and verified through independent laboratory analysis.
⚠️ FOR RESEARCH PURPOSES ONLY
This product is strictly for in-vitro laboratory research, analysis, and development. It is not intended for human consumption, injection, or therapeutic use. CJC-1295 No DAC is not a drug, dietary supplement, or food. All statements regarding the physiological mechanisms are based on preclinical animal and cell-culture studies and are provided for educational and informational purposes only.
Storage & Handling
Peptides require careful storage to maintain their integrity and research effectiveness. Lyophilized peptides should be stored in a cold, dry, dark environment to prevent degradation. For short-term use within 4 weeks, storage at 4°C is sufficient, while long-term storage requires temperatures below -20°C or -80°C for extended periods up to 2 years. Always protect peptides from light exposure and avoid repeated freeze-thaw cycles, which can compromise structural integrity and research results.

















